Christian G. Schutz

Biography

Dr. Schütz is a psychiatrist, with training and a research background in epidemiology as well as preclinical and clinical behavioral pharmacology. He studied in Vienna, Austria, Freiburg Germany and at Johns Hopkins University in Baltimore, USA. A Fogerty Fellowship at the Intramural Research Center of the National Institute of Drug Abuse/National Institute of Health complemented his clinical training. His psychiatric residency at Munich University, Germany was followed by a short fellowship in clinical neuroscience at Yale University, USA. Before joining the faculty of UBC in May 2008, he was Oberarzt (attending and lecturer) at the Department of Psychiatry at Bonn University, Germany. His responsibilities included patient care, teaching and research. His studies on risk factors for the development of substance dependence and relapse were funded by DFG (German Research Society), BMBF (German Ministry for Education and Research) and NIDA/NIH (National Institute of Drug Abuse, USA) and others (e.g. pharmaceutical companies). He recently focused on predicting treatment outcome and relapse, combining neuroimaging, neurocognition and genetic approaches with clinical and psychosocial measures. Dr. Schütz is a psychiatrist, with training and a research background in epidemiology as well as preclinical and clinical behavioral pharmacology. He studied in Vienna, Austria, Freiburg Germany and at Johns Hopkins University in Baltimore, USA. A Fogerty Fellowship at the Intramural Research Center of the National Institute of Drug Abuse/National Institute of Health complemented his clinical training. His psychiatric residency at Munich University, Germany was followed by a short fellowship in clinical neuroscience at Yale University, USA. Before joining the faculty of UBC in May 2008, he was Oberarzt (attending and lecturer) at the Department of Psychiatry at Bonn University, Germany. His responsibilities included patient care, teaching and research. His studies on risk factors for the development of substance dependence and relapse were funded by DFG (German Research Society), BMBF (German Ministry for Education and Research) and NIDA/NIH (National Institute of Drug Abuse, USA) and others (e.g. pharmaceutical companies). He recently focused on predicting treatment outcome and relapse, combining neuroimaging, neurocognition and genetic approaches with clinical and psychosocial measures.

Research Interest

Clinical and public health aspects of interventions in addictive disorders Neurobiological and psychosocial risk factors of mental disorders Co-occurring disorders